Acute vasodilator testing in idiopathic pulmonary arterial hypertension: Must we take NO for the answer?

European Respiratory Journal

Volumn 33, Issue 6, 2009, Pages 1247-1249

  Opitz, C F ^a   Rubin, L J ^b  

^a German Red Cross Hospital   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; DILTIAZEM; ILOPROST; NITRIC OXIDE; VASODILATOR AGENT;

DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDITORIAL; FUNCTIONAL ASSESSMENT; HEART RIGHT ATRIUM PRESSURE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LUNG ARTERY PRESSURE; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCORING SYSTEM; VASODILATATION; WALKING;

ADENOSINE; ADMINISTRATION, INHALATION; DILTIAZEM; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 69249145623     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00033809     Document Type: Editorial

References (19)

1. Wood P. Primary pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 20: 557-570.
2. Dresdale DT, Michtom RJ, Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954; 30: 195-207.
3. Harris P. Influence of acetylcholine on the pulmonary arterial pressure. Br Heart J 1957; 19: 272-278.
4. Wood P, Besterman EM, Towers MK, et al. The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart J 1957; 19: 279-286.
5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
6. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.
7. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
8. Barst R, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43, 12: Suppl. 1, S40-S47.
9. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
10. Badesch BD, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension. ACCP evidence-based guidelines for clinical practice. Chest 2004; 126: 35S-62S.
11. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126: Suppl. 1, 35S-62S.
12. Opitz CF, Wensel R, Bettmann M, et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: 356-365.
13. Hoeper MM, Olschewski H, Ghofrani HA, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
14. Hoeper MM, Lee SH, Voswinckel R, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48: 2546-2552.
15. Jing Z-C, Jiang X, Han Z-Y, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 33: 1351-1357.
16. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
17. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31: 891-901.
18. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-415.
19. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.